Metabolic risk factors in prostate cancer

Cancer

Volumn 117, Issue 10, 2011, Pages 2020-2023

  Chu, David I ^a,b   Freedland, Stephen J ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL;

APOPTOSIS; CANCER RISK; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS; HUMANS; MALE; METABOLIC SYNDROME X; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE; TRIGLYCERIDES;

EID: 79955506853     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25749     Document Type: Review

References (23)

1. Hsing AW, Sakoda LC, Chua S Jr., Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007; 86: s843-s857.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
3. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA., Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009; 169: 937-945.
4. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE., Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005; 161: 147-152. (Pubitemid 40096789)
5. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008; 9: 1039-1047.
6. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1977-1983. (Pubitemid 44664277)
7. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM., Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009; 124: 2416-2429.
8. DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A. 2000; 97: 3455-3460. (Pubitemid 30183324)
9. Svensson J, Kindblom J, Shao R, et al. Liver-derived IGF1 enhances the androgenic response in prostate. J Endocrinol. 2008; 199: 489-497.
10. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ., Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996; 88: 1118-1126. (Pubitemid 26274606)
11. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1262-1269. (Pubitemid 40656478)
12. Roddam AW, Allen NE, Appleby P, Key TJ., Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100: 170-183. (Pubitemid 351480553)
13. Ding EL, Song Y, Malik VS, Liu S., Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295: 1288-1299.
14. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study [published online ahead of print August 30, 2010]. J Sex Med. PMID: 20807333.
15. Saylor PJ, Smith MR., Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009; 181: 1998-2006; discussion 2007-2008.
16. Tande AJ, Platz EA, Folsom AR., The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006; 164: 1094-1102. (Pubitemid 44851745)
17. Freedland SJ, Wen J, Wuerstle M, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008; 72: 1102-1105.
18. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW., Obese men have higher-grade and larger tumors: an analysis of the Duke prostate center database. Prostate Cancer Prostatic Dis. 2009; 12: 259-263.
19. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625-1638. (Pubitemid 36459468)
20. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR., Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005; 115: 959-968. (Pubitemid 40489400)
21. Platz EA, Till C, Goodman PJ, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2807-2813.
22. Hamilton RJ, Freedland SJ., Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol. 2008; 18: 333-339. (Pubitemid 351489386)
23. Antonelli J, Freedland SJ, Jones LW., Exercise therapy across the prostate cancer continuum. Prostate Cancer Prostatic Dis. 2009; 12: 110-115.